Patents by Inventor Daniel L Flynn

Daniel L Flynn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20240376058
    Abstract: Described herein are compounds that are inhibitors of GCN2 kinase or PERK kinase, and methods of treating diseases, including diseases associated with GCN2 kinase or PERK kinase, with said compounds.
    Type: Application
    Filed: January 10, 2024
    Publication date: November 14, 2024
    Inventors: Daniel L. Flynn, Patrick Kearney, Jeffery Zwicker, Gada Al-Ani, Salim Javed, Yu Mi Ahn, Kristen Stoltz, Bertrand Le Bourdonnec
  • Combination therapy for the treatment of mastocytosis
    Patent number: 12102620
    Abstract: The present disclosure relates to the use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea, or a pharmaceutically acceptable salt thereof, in combination with a MAPKAP pathway inhibitor such as for example a RAS, RAF, MEK, or ERK inhibitor for the treatment of mastocytosis.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: October 1, 2024
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Bryan D. Smith, Anu Gupta
  • Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
    Patent number: 12071432
    Abstract: Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.
    Type: Grant
    Filed: June 6, 2022
    Date of Patent: August 27, 2024
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Yu Mi Ahn, Timothy Caldwell, Lakshminarayana Vogeti
  • METHODS OF TREATING DISORDERS WITH ULK INHIBITORS
    Publication number: 20240180923
    Abstract: Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.
    Type: Application
    Filed: August 29, 2023
    Publication date: June 6, 2024
    Inventors: Rodrigo Ruiz Soto, Frederic J. Reu, Matthew L. Sherman, Daniel L. Flynn, Madhumita Bogdan, Bryan D. Smith, Gada Al-Ani
  • Combination therapy for the treatment of gastrointestinal stromal tumor
    Patent number: 11986463
    Abstract: The present disclosure relates to the use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea, or a pharmaceutically acceptable salt thereof, in combination with a MAPKAP kinase inhibitor for the treatment of cancers, including c-KIT-mediated cancers, such as GIST.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: May 21, 2024
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Bryan D. Smith, Anu Gupta
  • ULK INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20240150368
    Abstract: Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.
    Type: Application
    Filed: August 28, 2023
    Publication date: May 9, 2024
    Inventors: Justin T. Proto, Andrew Michael Harned, Kristen Stoltz, Timothy Caldwell, Lakshminarayana Vogeti, Yu Mi Ahn, Bertrand Le Bourdonnec, Daniel L. Flynn
  • KIT KINASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20240116877
    Abstract: Described herein are compounds that are inhibitors of wild type and oncogenic mutant c-KIT kinase and their use in the treatment of disorders such as cancers.
    Type: Application
    Filed: December 2, 2022
    Publication date: April 11, 2024
    Inventors: Yu Mi Ahn, Timothy Caldwell, Daniel L. Flynn, Bertrand LeBourdonnec
  • GCN2 and perk kinase inhibitors and methods of use thereof
    Patent number: 11912668
    Abstract: Described herein are compounds, such as compounds represented by Formula I-R: and pharmaceutically acceptable salts, enantiomers, stereoisomers, and tautomers thereof, that are inhibitors of GCN2 kinase or PERK kinase, and methods of treating diseases, including diseases associated with GCN2 kinase or PERK kinase, with said compounds.
    Type: Grant
    Filed: November 17, 2021
    Date of Patent: February 27, 2024
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Patrick Kearney, Jeffery Zwicker, Gada Al-Ani, Salim Javed, Yu Mi Ahn, Kristen Stoltz, Bertrand Le Bourdonnec
  • METHODS OF TREATING DISORDERS USING CSF1R INHIBITORS
    Publication number: 20230414614
    Abstract: Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).
    Type: Application
    Filed: April 28, 2023
    Publication date: December 28, 2023
    Applicant: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Bryan D. Smith, Rodrigo Ruiz Soto, Keisuke Kuida
  • GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20230382915
    Abstract: Described herein are compounds that are inhibitors of GCN2 kinase or PERK kinase, and methods of treating diseases, including diseases associated with GCN2 kinase or PERK kinase, with said compounds.
    Type: Application
    Filed: December 2, 2022
    Publication date: November 30, 2023
    Inventors: Yu Mi Ahn, Gada Al-Ani, Daniel L. Flynn, Salim Javed, Patrick Kearney, Bertrand LeBourdonnec, Kristen Stoltz, Jeffery Zwicker
  • RAF KINASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20230357179
    Abstract: Described herein are compounds that are RAF inhibitors and their use in the treatment of disorders such as cancers.
    Type: Application
    Filed: December 9, 2022
    Publication date: November 9, 2023
    Inventors: Daniel L. Flynn, Yu Mi Ahn, Lakshminarayana Vogeti, Bertrand Le Bourdonnec
  • Anti-viral activity of VPS34 inhibitors
    Patent number: 11801238
    Abstract: Described herein, in part, are methods of treating viral infections, such as coronavirus infections, in patients in need thereof, comprising administering to the patients a VPS34 inhibitor.
    Type: Grant
    Filed: November 24, 2021
    Date of Patent: October 31, 2023
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventor: Daniel L. Flynn
  • AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20230338376
    Abstract: Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.
    Type: Application
    Filed: January 11, 2023
    Publication date: October 26, 2023
    Inventors: Daniel L. Flynn, Yu Mi Ahn, Timothy Caldwell, Lakshminarayana Vogeti
  • METHODS FOR TREATING VASCULAR MALFORMATIONS
    Publication number: 20230277522
    Abstract: The present disclosure relates to methods for inhibiting TIE2 kinase useful in the treatment of growth of venous malformations.
    Type: Application
    Filed: August 12, 2020
    Publication date: September 7, 2023
    Inventors: Daniel L. Flynn, Bryan D. Smith, Miikka Vikkula
  • RAF KINASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20230257352
    Abstract: Described herein are compounds that are RAF inhibitors and their use in the treatment of disorders such as cancers.
    Type: Application
    Filed: December 9, 2022
    Publication date: August 17, 2023
    Inventors: Daniel L. Flynn, Yu Mi Ahn, Lakshminarayana Vogeti, Bertrand Le Bourdonnec
  • Methods of treating disorders using CSF1R inhibitors
    Patent number: 11679110
    Abstract: Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: June 20, 2023
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Bryan D. Smith, Rodrigo Ruiz Soto, Keisuke Kuida
  • Aminopyrimidine amide autophagy inhibitors and methods of use thereof
    Patent number: 11590134
    Abstract: Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: February 28, 2023
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Yu Mi Ahn, Timothy Caldwell, Lakshminarayana Vogeti
  • HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20230047915
    Abstract: Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.
    Type: Application
    Filed: June 3, 2022
    Publication date: February 16, 2023
    Inventors: Daniel L. Flynn, Yu Mi Ahn, Timothy Caldwell, Lakshminarayana Vogeti
  • PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20230039712
    Abstract: Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.
    Type: Application
    Filed: June 6, 2022
    Publication date: February 9, 2023
    Inventors: Daniel L. Flynn, Yu Mi Ahn, Timothy Caldwell, Lakshminarayana Vogeti
  • Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
    Patent number: 11530206
    Abstract: Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: December 20, 2022
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Yu Mi Ahn, Timothy Caldwell, Lakshminarayana Vogeti